ECDC surveillance report on Legionnaires’ disease in Europe in 2010
ECDC published its annual surveillance report on Legionnaires’ disease in Europe in 2010. In 2010, a total of 6 296 cases of Legionnaires’ disease were notified by EU Member States, Iceland and Norway, with a 11% increase from 2009. The majority of the cases were community-acquired, while around 20% were travel-associated.
ECDC published its annual surveillance report on Legionnaires’ disease in Europe in 2010.
In 2010, a total of 6 296 cases of Legionnaires’ disease were notified by EU Member States, Iceland and Norway, with a 11% increase from 2009. The majority of the cases were community-acquired, while around 20% were travel-associated.
The surveillance activity was carried out by the European Legionnaires’ Disease Surveillance Network (ELDSNet) and coordinated by ECDC. This is the second annual report presenting the analysis of Legionnaires’ disease (LD) surveillance data in Europe. Data were collected through two different schemes, the first scheme covering all cases of LD reported from ELDSNet members, while the second scheme covers all reported cases of travel-associated Legionnaires’ disease (TALD), including reports from countries outside the EU. This document is therefore the first annual report that includes all reported cases of LD and TALD.
Collecting data on TALD at EU-level is crucial to identify and tackle clusters of Legionnaires’ disease that may not have been identified at a national level, particularly because in Europe, notification rates and laboratory diagnostic practice highly differ among countries.
Legionnaires’ disease is a multisystem disease involving pneumonia. Humans are infected by inhalation of aerosols containing Legionella bacteria. The diagnosis relies on specific laboratory tests, and the disease is considered to be widely underreported, mainly because it is under diagnosed by clinicians and under-notified to national authorities. The ELDSNet should continue its efforts on improving notification in countries where under-ascertainment probably remains quite high, especially by raising awareness, providing laboratory support and training, and evaluating the surveillance systems in place.
Read the full report ‘Legionnaires’ disease in Europe – 2010’
Because it’s best to know: start of European HIV-Hepatitis testing week
An estimated 122 000 people living with HIV across Europe are not aware of their HIV infection and a large number out of the estimated 9 million Europeans that are affected by chronic hepatitis B or C have not yet been tested or diagnosed. ECDC welcomes the efforts of European HIV-Hepatitis Testing Week which starts today.Read more
Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from ECDC
On the occasion of the 10th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) published a new guidance on how to prevent the entry and spread of carbapenemase-producing Enterobacteriaceae (CRE) into healthcare settings. The guidance features a series of tables and a flowchart with information on how to assess and manage patients who may be “at-risk” for carrying CRE when they are admitted to a healthcare setting. These easy-to-use tables and flowchart can hopefully be helpful to healthcare workers to easily identify those “at-risk” patients and implement appropriate infection prevention and control measures in a timely manner.Read more
Combined resistance to multiple antibiotics: a growing problem in the EU
On the occasion of the 10th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) is releasing its latest EU-wide data on antibiotic resistance, as well as its guidance on prevention and control of carbapenem-resistant Enterobacter iaceae (CRE). In 2016, combined resistance to several antibiotic groups continued to increase for Escherichia coli and Acinetobacter species. This situation is of great concern as patients infected with these multidrugresistant bacteria have very limited treatment options.